Literature DB >> 9135025

CD97: a dedifferentiation marker in human thyroid carcinomas.

G Aust1, W Eichler, S Laue, I Lehmann, N E Heldin, O Lotz, W A Scherbaum, H Dralle, C Hoang-Vu.   

Abstract

CD97 is a dimeric glycoprotein of Mr 75,000-85,000 and 28,000 belonging to a novel subfamily of seven-span transmembrane region leukocyte cell surface molecules. It is expressed abundantly in cells of hematopoietic origin. This is the first report demonstrating the expression of CD97 outside the hematopoetic system. CD97 was studied in normal human and neoplastic follicular epithelium of the thyroid and anaplastic (n = 3) and papillary (n = 1) thyroid carcinoma cell lines. In normal thyroid tissue (n = 11), no immunoreactivity of CD97 could be found, whereas in differentiated thyroid carcinomas (n = 10), CD97 expression was either lacking or low. Eleven of 12 undifferentiated anaplastic carcinomas revealed high CD97 presentation. CD97 was absent or only weakly present in patients with postoperative T1 tumors but increased greatly with the progression to postoperative T4 tumors. CD97 is clearly present in thyroid carcinoma cell lines but only at a very low level in normal human thyrocytes. Quantitation of CD97 cell surface expression levels revealed that C 643 and SW 1736 cells showed a two to four times higher specific antibody-binding capacity than did 8505 C and HTh 74 cells and a nearly 20 times higher specific antibody-binding capacity than normal thyrocytes. Phorbol 12-myristate 13-acetate treatment progressively caused a decrease of CD97 antigen expression in all cell lines to about 30% of their initial levels after 48 h. Immunohistochemical staining of SW 1736 cells revealed that CD97 is located in most of the cell compartments and suggested a CD97 internalization process after phorbol 12-myristate 13-acetate treatment. Semiquantitative reverse transcription-PCR showed a correlation of CD97 mRNA and cell surface CD97 expression level in the cell lines. SW 1736, HTh 74, and 8505 C cells apparently expressed CD97 with alternative glycosylation compared to peripheral lymphocytes, whereas most of the CD97 antigen presented on thyrocytes and C 643 cells had glycosylation sites resembling those of lymphocytes. The data suggest that CD97 expression may be a sensitive marker of dedifferentiation and of lymph node involvement in human thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Adhesion G Protein-Coupled Receptors: From In Vitro Pharmacology to In Vivo Mechanisms.

Authors:  Kelly R Monk; Jörg Hamann; Tobias Langenhan; Saskia Nijmeijer; Torsten Schöneberg; Ines Liebscher
Journal:  Mol Pharmacol       Date:  2015-05-08       Impact factor: 4.436

2.  The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.

Authors:  Shao-Liang Han; Chang Xu; Xiu-Ling Wu; Jun-Lin Li; Zhi Liu; Qi-Qiang Zeng
Journal:  Int J Colorectal Dis       Date:  2010-03-26       Impact factor: 2.571

3.  Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

Authors:  W Voigt; T Kegel; M Weiss; T Mueller; H Simon; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 4.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

5.  CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway.

Authors:  Chao Li; Da-Ren Liu; Guo-Gang Li; Hou-Hong Wang; Xiao-Wen Li; Wei Zhang; Yu-Lian Wu; Li Chen
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

6.  Role of CD97 small isoform in human cervical carcinoma.

Authors:  Ying He; Lian Xu; Min Feng; Wei Wang
Journal:  Int J Exp Pathol       Date:  2019-03-18       Impact factor: 1.925

7.  Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.

Authors:  Matthias Steinert; Manja Wobus; Carsten Boltze; Alexander Schütz; Mandy Wahlbuhl; Jörg Hamann; Gabriela Aust
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

8.  Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).

Authors:  Y M Qian; M Haino; K Kelly; W C Song
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

9.  Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients.

Authors:  Yong Liu; Li Chen; Shu-You Peng; Zhou-Xun Chen; C Hoang-Vu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

10.  Overexpression of CD97 in intestinal epithelial cells of transgenic mice attenuates colitis by strengthening adherens junctions.

Authors:  Susann Becker; Elke Wandel; Manja Wobus; Rick Schneider; Salah Amasheh; Doreen Sittig; Christiane Kerner; Ronald Naumann; Joerg Hamann; Gabriela Aust
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.